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Binge eating afflicts approximately 5% of US adults, though effective treatments are limited. Here, we showed that
estrogen replacement substantially suppresses binge-like eating behavior in ovariectomized female mice. Estrogendependent inhibition of binge-like eating was blocked in female mice specifically lacking estrogen receptor-α (ERα) in
serotonin (5-HT) neurons in the dorsal raphe nuclei (DRN). Administration of a recently developed glucagon-like peptide1–estrogen (GLP-1–estrogen) conjugate designed to deliver estrogen to GLP1 receptor–enhanced regions effectively
targeted bioactive estrogens to the DRN and substantially suppressed binge-like eating in ovariectomized female mice.
Administration of GLP-1 alone reduced binge-like eating, but not to the same extent as the GLP-1–estrogen conjugate.
Administration of ERα-selective agonist propylpyrazole triol (PPT) to murine DRN 5-HT neurons activated these neurons
in an ERα-dependent manner. PPT also inhibited a small conductance Ca2+-activated K+ (SK) current; blockade of the
SK current prevented PPT-induced activation of DRN 5-HT neurons. Furthermore, local inhibition of the SK current in the
DRN markedly suppressed binge-like eating in female mice. Together, our data indicate that estrogens act upon ERα to
inhibit the SK current in DRN 5-HT neurons, thereby activating these neurons to suppress binge-like eating behavior and
suggest ERα and/or SK current in DRN 5-HT neurons as potential targets for anti-binge therapies.

Find the latest version:
https://jci.me/74726/pdf
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Binge eating afflicts approximately 5% of US adults, though effective treatments are limited. Here, we showed that estrogen
replacement substantially suppresses binge-like eating behavior in ovariectomized female mice. Estrogen-dependent
inhibition of binge-like eating was blocked in female mice specifically lacking estrogen receptor-α (ERα) in serotonin (5-HT)
neurons in the dorsal raphe nuclei (DRN). Administration of a recently developed glucagon-like peptide-1–estrogen
(GLP-1–estrogen) conjugate designed to deliver estrogen to GLP1 receptor–enhanced regions effectively targeted bioactive
estrogens to the DRN and substantially suppressed binge-like eating in ovariectomized female mice. Administration of GLP-1
alone reduced binge-like eating, but not to the same extent as the GLP-1–estrogen conjugate. Administration of ERα-selective
agonist propylpyrazole triol (PPT) to murine DRN 5-HT neurons activated these neurons in an ERα-dependent manner. PPT
also inhibited a small conductance Ca2+-activated K+ (SK) current; blockade of the SK current prevented PPT-induced activation
of DRN 5-HT neurons. Furthermore, local inhibition of the SK current in the DRN markedly suppressed binge-like eating in
female mice. Together, our data indicate that estrogens act upon ERα to inhibit the SK current in DRN 5-HT neurons, thereby
activating these neurons to suppress binge-like eating behavior and suggest ERα and/or SK current in DRN 5-HT neurons as
potential targets for anti-binge therapies.

Introduction

Binge eating is defined as the ingestion of a large amount of food
in a brief period of time and is characterized by the preferential
choice of highly palatable food. Binge eating, afflicting approximately 5% of US adults (1), is a central trait of major eating disorders, such as the binge-eating/purging type anorexia nervosa
(AN), bulimia nervosa (BN), binge-eating disorder (BED), and
other eating disorders not otherwise specified (EDNOS) (2, 3).
Binge eating constitutes a significant public health concern by virtue of its strong associations with other medical and psychiatric
disorders, most notably obesity and depression (1). Development
of more effective treatments for binge eating is urgently needed.
Binge eating is more prevalent in women than in men, and
women with binge eating often suffer from menstrual irregularity, presumably due to impaired functions of ovarian hormones
(e.g., estrogens) (4–6). Interestingly, circulating 17β-estradiol levels
are inversely associated with binge eating in women (7–11). Consistently, removal of endogenous ovarian hormones by ovariectomy
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(OVX) potentiates binge eating in female rats (12), whilereplacement with 17β-estradiol and progesterone in OVX rats suppresses
binge eating (13). While these data suggest that hormone replacement therapy could be used to suppress binge-like eating, at least
in women, the clinical application of ovarian hormones, e.g., estrogens, is limited by their gynecological and tumor-promoting actions.
Therefore, better understanding the mechanisms by which ovarian
hormones regulate binge-eating behavior may facilitate development of more selective hormone-based therapies that effectively
inhibit binge eating but cause few or no side effects in humans.
Impaired brain serotonin (5-HT) signaling has been implicated in the development of binge eating (14–16). Interestingly,
drugs that increase brain 5-HT content, such as fluoxetine, have
been shown to suppress binge eating in humans (17–22). Notably,
d-fenfluramine, a drug that increases 5-HT content by stimulating
synaptic release of 5-HT and blocking its reuptake (23), effectively
reduces the number of binge episodes in patients (24, 25). These
findings suggest that brain 5-HT neurons play an important role in
the regulation of binge-eating behavior.
Emerging evidence suggests that estrogens directly act on
brain 5-HT neurons. For example, estrogen receptors, including
estrogen receptor-α (ERα), are abundantly expressed in the dorsal
raphe nuclei (DRN) (26), where most 5-HT neurons are located.
Further, estrogen replacement increases neural activities in the
jci.org   Volume 124   Number 10   October 2014
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Figure 1. Estrogen replacement inhibits binge-like eating in female mice. (A and B) C57BL/6 female mice (12 weeks) were ovariectomized and implanted
with s.c. 17β-estradiol pellets (0.5 μg/d for 60 days; OVXE) or vehicle pellets (OVXV). After a 7-day recovery, mice were subjected to intermittent HFD exposure or continuous HFD exposure for 1 week, as described in Methods. At the beginning of the next week, HFD and chow diet were provided to cages at
11:00 am, and 2.5-hour HFD intake (A) and chow intake (B) was measured. (C) Body weight was measured on the same day when binge-like behavior was
assessed. n = 6–7/group. Results are shown as mean ± SEM. **P < 0.01; ***P < 0.001 between OVXV and OVXE mice in 2-way ANOVA analyses followed by
post hoc Bonferroni’s test.

DRN (27, 28). Based on these, we hypothesized that estrogens
directly act through DRN 5-HT neurons to inhibit binge eating.
To test this hypothesis, we first examined whether estrogens
regulate binge-like eating behavior in female mice. Then, using
a genetic mouse model lacking ERα only in 5-HT neurons in the
DRN, we tested to determine whether ERα in DRN 5-HT neurons
is required to mediate the effects of estrogens on binge-like eating behavior. We further tested the effects of a newly developed
glucagon-like peptide-1–estrogen (GLP-1–estrogen) conjugate on
binge-like eating behavior in female mice. Finally, we tested to
determine whether a small conductance Ca2+-activated K+ (SK)
current mediates estrogenic actions on 5-HT neural activities and
on binge-like eating behavior.

Results

17β-Estradiol inhibits binge-like eating in OVX female mice. Czyzyk
et al. recently showed that mice subjected to an intermittent highfat diet (HFD) exposure paradigm display recurring binge-like eating behavior compared with mice subjected to a continuous HFD
exposure paradigm (29). To test the effects of estrogens on bingelike eating behavior, female C57BL/6 mice received bilateral OVX,
followed by s.c. implantations of pellets containing 17β-estradiol
(0.5 μg/d for 60 days, OVXE) or containing vehicle (OVXV). After
a 7-day recovery from the surgery, OVXV and OVXE female mice
were subjected to intermittent HFD exposure or continuous HFD
exposure for 1 week (as detailed in Methods). On the day to assess
binge-like eating behavior (2 weeks after the surgeries), intake of
HFD and chow was measured for 2.5 hours (from 11:00 am to 1:30
pm). First, OVXE significantly decreased HFD intake compared
with OVXV treatment in mice exposed to intermittent HFD, while
in mice exposed to continuous HFD, HFD intake was minimal and
comparable between OVXE and OVXV groups (Figure 1A). Chow
intake was minimal in all 4 groups (Figure 1B). In particular, OVXE
significantly increased chow intake compared with OVXV in mice
exposed to intermittent HFD, while such a difference was not
observed between OVXV and OVXE mice exposed to continuous
HFD (Figure 1B). In addition, we showed that body weights in all 4
groups were comparable on the binge assessment day (Figure 1C),
suggesting that effects of estrogens on binge-like eating behavior
4352
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were not confounded by different body weights. Together, these
results indicate that estrogen replacement in OVX female mice
effectively suppresses binge-like eating behavior.
Importantly, we demonstrated that female mice exposed to
either continuous or intermittent HFD displayed similar anxiety
levels and locomotor activities measured in the light-dark test
and the elevated plus maze (EPM) test (Supplemental Figures 1
and 2; supplemental material available online with this article;
doi:10.1172/JCI74726DS1). Similarly, the forced swim test did not
detect significant differences in depression levels in mice exposed
to continuous or intermittent HFD (Supplemental Figure 3). These
results suggest that binge-like behavior we observed in the “intermittent” group is unlikely to be associated with different anxiety
and/or depression levels.
ERα in 5-HT neurons mediates inhibitory effects of estrogens on
binge-like eating. We used double immunofluorescence to examine
colocalization of ERα and 5-HT in female C57BL/6 mouse brains.
We found that about 40% of 5-HT neurons in the DRN coexpress
ERα; about 90% of ERα neurons in this region are 5-HTergic (Figure 2A). None to few 5-HT neurons in the median raphe nuclei or
caudal raphe nuclei (MRN or CRN) coexpress ERα (Figure 2, B and
C). These results raise the possibility that ERα expressed by DRN
5-HT neurons may be involved in the estrogenic effects on bingelike eating behavior.
In order to specifically target 5-HT neurons in functional mice,
we first validated a Tph2-CreER mouse line in which expression
of tamoxifen-inducible Cre recombinase is driven by tryptophan
hydroxylase 2 (Tph2) promoter. To this end, Tph2-CreER mice were
crossed to Rosa26-tdTOMATO mice to generate Tph2-CreER Rosa26tdTOMATO mice. Upon tamoxifen induction (3 mg/injections, i.p.,
twice, 24 hours apart), the strong red fluorescence (TOMATO) was
observed in the DRN, MRN, and CRN. Using double immunofluorescence for 5-HT (green) and TOMATO staining (red), we confirmed that all TOMATO-positive neurons are exclusively 5-HT
neurons (Supplemental Figure 4, A–C). Importantly, no TOMATO
signals were observed in other non–5-HT regions, including the
arcuate nucleus (ARH), the ventromedial hypothalamic nucleus
(VMH), and the paraventricular nucleus of the hypothalamus (PVH)
(Supplemental Figure 5, A and B). In addition, as a negative control,
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ble body weight, fat mass, and lean mass when binge-like
eating behavior was assessed (Figure 3F). No difference
in plasma orexin A levels was observed among these 4
groups (Figure 3G). These results indicate that the inhibitory effects of estrogens on binge-like eating behavior in
female mice are largely mediated by ERα expressed by
DRN 5-HT neurons.
GLP-1–estrogen targets the DRN and inhibits binge-like
eating. A stable GLP-1–estrogen conjugate was recently
developed to preferentially deliver estrogens to GLP-1
receptor–enriched regions, but does not release estrogens
into the circulation (31). GLP-1–estrogen has been shown
to produce profound estrogen-mediated metabolic benefits in animals, while the common side effects associated
with estrogen therapy (e.g., reproductive endocrine toxicity and breast cancer) are avoided (31). Interestingly, the
DRN expresses abundant GLP-1 receptors (32). Further,
we showed that injections of GLP-1–estrogen (4 μg/kg,
s.c., 2 hours) significantly increased expression of tripartite motif–containing protein 25 (Trim25, a known estrogen target) in the DRN of OVX female C57BL/6 mice
(Figure 4A). A similar increase in Trim25 mRNA was also
observed in OVXE mice (Figure 4A). Importantly, GLP-1
(4 μg/kg) did not alter Trim25 mRNA in the DRN (Figure
4A). These results indicate that GLP-1–estrogen conjugate
delivers bioactive estrogens to the DRN in addition to other
sites (e.g., the hypothalamus) (31) and therefore raise the
possibility that GLP-1–estrogen may act upon ERα in the
DRN to inhibit binge-like eating behavior. To test this, we
examined binge-like eating behaviors in OVX WT female
mice 30 minutes after they received injections of saline,
Figure 2. 5-HT neurons express ERα. Representative immunofluorescent images
GLP-1, or GLP-1–estrogen. Interestingly, we observed
for 5-HT (left, green) and ERα (middle, red) in coronal mouse brain sections containthat GLP-1 (4 μg/kg, s.c.) significantly reduced binge-like
ing the DRN (A), MRN (B), and CRN (C). Yellow neurons in the right panels indicate
eating behavior (measured by 2.5-hour HFD intake) com5-HT neurons that coexpress ERα. Scale bars: 100 μm. Aq, aqueduct; PAG,
periaqueductal gray; py, pyramidal tract.
pared with saline treatment, by about 33% (Figure 4B).
Importantly, GLP-1–estrogen (4 μg/kg, s.c.) produced a
significantly more robust inhibition on binge-like eating
behavior, by about 66% (Figure 4B), confirming that a portion
we checked TOMATO staining in Tph2-CreER Rosa26-tdTOMATO
of the effects induced by this conjugate stem from estrogens. In
mice without tamoxifen injections. No TOMATO signal was detectaddition, we showed that effects of GLP-1 and GLP-1–estrogen on
ed in these mice (data not shown), indicating that there is no leakage
binge-like eating behavior were comparable in OVX female mice
of Cre activity in Tph2-CreER mice.
with ERα selectively deleted in the DRN (Figure 4B), indicating
To test whether ERα expressed by 5-HT neurons is required
that estrogen-mediated inhibition on binge-like eating behavto mediate the inhibitory effects of estrogens on binge-like eatior requires ERα expressed by 5-HT neurons. As expected, the
ing behavior, we crossed Tph2-CreER to Esr1fl/fl mice (30). This
inhibitory effects induced by GLP-1 alone were not affected in KO
cross generated Esr1fl/fl (WT) and Esr1fl/fl Tph2-CreER (KO) mice.
mice (Figure 4B), since GLP-1’s effects are presumably mediated
We validated that in KO mice (after tamoxifen induction), ERα
by GLP-1 receptors. Given that GLP-1–estrogen has been shown
was selectively deleted from the DRN, but ERα in other non–
to avoid the common side effects associated with estrogens, our
5-HT regions (including ARH and VMH) was intact (Figure 3,
results provided the experimental basis that this newly developed
A–D). Both WT and KO mice (after tamoxifen induction) were
conjugate, or its modified forms, could be used to treat binge
divided into 2 groups to receive OVXV or OVXE treatment and
eating, at least in women.
then subjected to intermittent HFD exposure to induce bingeBasic electrophysiological properties of identified DRN 5-HT
like eating behavior. We showed that in WT mice, OVXE treatneurons from WT and KO mice. In order to delineate the cellular
ment significantly suppressed binge-like eating behavior (meamechanisms by which ERα signals regulate 5-HT neurons, we
sured by 2.5-hour HFD intake) compared with that in OVXV
crossed the Rosa26-tdTOMATO allele to both Tph2-CreER and
mice (Figure 3E). In contrast, both OVXV and OVXE KO mice
Esr1fl/fl Tph2-CreER mice. This generated Tph2-CreER Rosa26showed comparable binge-like eating behavior (Figure 3E). In
addition, we found that WT and KO female mice had comparatdTOMATO (WT) and Esrfl/fl Tph2-CreER Rosa26-tdTOMATO
jci.org   Volume 124   Number 10   October 2014
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Figure 3. ERα in 5-HT neurons mediates
estrogenic actions to inhibit binge-like
eating in female mice. (A–D) Representative immunohistochemistry for ERα from
female WT (A and C) and KO (B and D) mice
(after tamoxifen inductions). Scale bars:
100 μm. 3V, third ventricle; ME, median
eminence. (E) WT and KO mice received
tamoxifen inductions at 8 weeks of age (3
mg/injections, i.p., 24 hours apart). At 24
weeks of age, mice were ovariectomized
and implanted with s.c. 17β-estradiol pellets (0.5 μg/d for 60 days; OVXE) or vehicle
pellets (OVXV). After a 7-day recovery, mice
were subjected to intermittent HFD exposure for 1 week, as described in Methods. At
the end of that week, HFD and chow diet
were provided to cages at 11:00 am, and 2.5hour HFD intake was measured. n = 7–10/
group. Results are shown as mean ± SEM.
***P < 0.001, between OVXV and OVXE
mice in 2-way ANOVA analyses followed by
post hoc Bonferroni’s tests. (F) Body weight,
fat mass, and lean mass of WT and KO mice
measured when binge-like behavior was
assessed. n = 16 or 18/group. Results are
shown as mean ± SEM. (G) Plasma orexin A
measured in WT and KO mice after assessment of binge-like eating behavior. n = 6–7/
group. Results are shown as mean ± SEM.

(KO) mice. We used these mice (after tamoxifen induction) to
perform electrophysiological recordings in identified 5-HT neurons (Figure 5, A–E). We first assessed the basic electrophysiological properties of identified DRN 5-HT neurons from WT and KO
mice. Thus, passive membrane properties, including input resistance and resting membrane potential (RM), were determined
by a series of 1-second hyperpolarizing current pulses from –160
pA to 0 pA, with steps of 20 pA (as an inset in Supplemental Figure 6). Input resistance was determined by the slope of a linear
regression fitted line of a current-voltage (I-V) curve. RM was
measured as the membrane voltage in the absence of current
injection. The input resistances of 5-HT neurons from KO mice
(493.90 ± 2.90 MΩ, n = 18) were higher than those in WT mice
(401.30 ± 1.74 MΩ, n = 26, P < 0.05 by t test, Supplemental Figure 6, A–C). There was no significant difference in RM of DRN
5-HT neurons between WT and KO mice (WT: –41.97 ± 1.527 mV,
n = 26; KO: –43.82 ± 2.65 mV, n = 18, P > 0.05 by t test, Supplemental Figure 6C). Further, we examined the characteristics of tonic
or phasic firing in 5-HT neurons by observing action potential
(AP) behavior of these neurons after direct depolarizing current
injections ranged from 0 to 300 pA for 1 second (as an inset in
Supplemental Figure 7A). We found that 84.38 % (27/32) WT and
77.78% (14/18) KO 5-HT neurons fired tonically (P > 0.05 by χ2
test, Supplemental Figure 7, A–E). In addition, we examined the
characteristics of spontaneous or evoked firing in 5-HT neurons.
We found that a larger proportion of 5-HT neurons fired spontaneously in KO mice compared with WT mice (WT: 59.38%, 19/32
vs. KO: 100%, 18/18, P < 0.05 by χ2 test, Supplemental Figure 8A).
4354
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Finally, AP properties, including firing frequency, the amplitude
of AP, the AP duration at 50% (APD50), and the amplitude of
after-hyperpolarization potential (AHPA) in spontaneous firing
neurons were analyzed. No significant differences were detected
in these parameters in the DRN 5-HT neurons between WT and
KO mice (Supplemental Figure 8, B–E).
Effects of the ERα agonist on DRN 5-HT neurons. We showed
that treatment with propylpyrazole triol (PPT) (100 nM), a selective ERα agonist, depolarized the RM (> 1 mV) in a proportion of
5-HT neurons from WT mice (53.13%, 17/32, Figure 5F), which
is largely consistent with our earlier observation that only 40%
of 5-HT neurons in the DRN coexpress ERα. Depending on the
magnitude of PPT-induced depolarization, we defined all WT
5-HT neurons as “responsive neurons” (> 1 mV) or “irresponsive neurons” (≤ 1 mV). Lack of PPT’s effects in the irresponsive
neurons was presumably because these neurons did not express
ERα. Supporting this possibility, we showed that the majority of
5-HT neurons from KO mice (which lack ERα selectively in 5-HT
neurons) were not depolarized by PPT (Figure 5G). Indeed, only
5.56% of(1/18) 5-HT neurons from KO mice responded to PPT
with a depolarization (> 1 mV), which was significantly less frequent than in WT mice (KO: 5.56%, 1/18 in KO vs. WT: 53.13%,
17/32; P < 0.001 by χ2 test, Figure 5I). Further, the magnitude
of PPT-induced depolarization in responsive neurons was significantly higher than those in irresponsive neurons and in 5-HT
neurons from KO mice (P < 0.001 by 1-way ANOVA, Figure 5J).
We further analyzed properties of AP in 5-HT neurons with spontaneous firing. Thus, we showed that PPT robustly increased
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Figure 4. GLP-1–estrogen inhibits binge-like eating in female mice partly through estrogenic actions on ERα in 5-HT neurons. (A) Real-time RT-PCR
analyses for Trim25 mRNAs in the DRN from female OVX mice receiving s.c. implantation of placebo pellets (OVXV), 17β-estradiol pellets (0.5 μg/d for
2 weeks; OVXE), single injection of GLP-1 (4 μg/kg, s.c., 2 hours; OVX + GLP-1), or GLP-1–estrogen (4 μg/kg, s.c., 2 hours; OVX + GLP-1–estrogen).
n = 4–6/group. Results are shown as mean ± SEM. *P < 0.05 and **P < 0.01 vs. OVXV; #P < 0.05 vs. OVX+GLP-1 in 1-way ANOVA analyses followed
by post hoc Bonferroni’s tests. (B) WT and KO mice (24 weeks) were ovariectomized. After a 7-day recovery, mice were subjected to intermittent HFD
exposure for 1 week, as described in Methods. At the end of that week, mice received s.c. injections of saline, GLP-1 (4 μg/kg), or GLP-1–estrogen
(4 μg/kg) at 10:30 am, and HFD and chow diet were provided to cages at 11:00 am; 2.5-hour HFD intake was measured. n = 8 or 9/group. Results are
shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 in 1-way ANOVA analyses followed by post hoc Bonferroni’s tests.

firing rates of responsive neurons from WT mice, while this effect
was significantly abolished in irresponsive neurons from WT
mice and in 5-HT neurons from KO mice (P < 0.001 by 1-way
ANOVA, Figure 5K). Finally, we also observed that PPT robustly
decreased AHPA in all responsive neurons from WT mice, but
not in irresponsive neurons from WT mice or in 5-HT neurons
from KO mice (P < 0.001 by 1-way ANOVA, Figure 5L). Together,
these results indicate that PPT activates DRN 5-HT neurons via
ERα-dependent mechanisms.
The ERα agonist activates DRN 5-HT neurons partly by inhibiting an apamin-sensitive SK current. The small conductance SK
currents have been implicated in the regulation of firing properties and AHP of neurons (33). Thus, we assessed effects of PPT
on SK-like currents in 5-HT neurons, using a published voltage clamp protocol (Figure 6A and ref. 34). We found that this
protocol induced robust currents in WT 5-HT neurons, which
were abolished by acute perfusion of apamin (100 nM, 8 minutes, Figure 6B). These data confirmed that these currents are
apamin-sensitive SK-like currents. Further, we showed that PPT
inhibited the SK-like currents in WT responsive neurons, but
such PPT effects were absent in irresponsive neurons from WT
mice, in 5-HT neurons from KO mice, and in WT 5-HT neurons
preincubated with 100 nM apamin for 2 hours (P < 0.05 by 1-way
ANOVA, Figure 6, C–F). Collectively, these results indicate that
PPT, via acting upon ERα, inhibits an apamin-sensitive SK-like
current in DRN 5-HT neurons.
To further determine whether the inhibition of the SK-like current contributes to PPT-induced activation of DRN 5-HT neurons,
we assessed effects of PPT on WT 5-HT neurons after preincubation of apamin (2 hours, 100 nM). After apamin preincubation,
the majority of WT 5-HT neurons were not depolarized by PPT
(responsive neurons in untreated WT: 53.13%, 17/32; responsive
neurons in apamin-treated WT: 12.5%, 2/16; P < 0.001 by χ2 test,
Figure 5I). The magnitude of PPT-induced depolarization in RM
was abolished in apamin-treated 5-HT neurons (P < 0.01 by 1-way

ANOVA, Figure 5J). Similarly, apamin also significantly abolished
PPT’s effects on firing rate (P < 0.001 by 1-way ANOVA, Figure 5K)
and AHPA (P < 0.001 by 1-way ANOVA, Figure 5L). These results
indicate that PPT activates DRN 5-HT neurons at least partly by
inhibiting the apamin-sensitive SK-like current.
Local inhibition of the SK current in the DRN suppresses bingelike eating. To test whether the SK current in 5-HT neurons is physiologically relevant for binge-like eating behavior, female mice
received stereotaxic injections of apamin or vehicle into the DRN
30 minutes prior to measurement of binge-like eating behavior. We found that, compared with vehicle-treated OVXV WT
mice, OVXV WT mice receiving intra-DRN injections of apamin
(50 nM, 0.5 μl) showed significantly suppressed binge-like eating
behavior, recapitulating responses seen in vehicle-treated OVXE
WT mice (Figure 6G). Similarly, intra-DRN injections of apamin
significantly suppressed binge-like eating behavior in OVXV KO
mice (Figure 6G), suggesting that effects of SK current inhibition
are likely downstream of ERα signals. Finally, in the conditioned
taste-aversion tests, we showed that intra-DRN injections of
apamin (50 nM, 0.5 μl) in OVX WT mice did not alter solution
intake compared with saline injections (Figure 6H), suggesting
that the inhibitory effects of apamin on binge-like eating behavior
were not due to adverse effects per se.

Discussion

One major finding of these studies is that OVXE WT mice
showed substantially decreased binge-like eating behavior
compared with OVXV WT mice. This observation is in line with
earlier reports that OVX rats show potentiated binge-like eating compared with gonad-intact female rats (12), while replacement with 17β-estradiol and progesterone suppresses binge-like
eating in female OVX rats (13). Here, we further pinpointed
that estrogen replacement alone can efficiently suppress bingelike eating behavior in female mice. Importantly, we assessed
the binge-like eating behavior 2 weeks after OVXV and OVXE
jci.org   Volume 124   Number 10   October 2014
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Figure 5. An ERα agonist activates DRN 5-HT neurons. (A–C) Brightfield (A), fluorescent with FRITC filter (B), and with FITC filter (C) illuminations of a
targeted DRN 5-HT neuron. Scale bars: 10 μm. (D and E) Post hoc identification of the recorded neuron within the DRN in the fixed brain slice. Scale bars:
100 μm (D); 20 μm (E). (F–H) Representative traces before and after PPT treatment in 5-HT neurons from WT mice (F), in 5-HT neurons from KO mice (G),
and in WT 5-HT neurons preincubated with 100 nM apamin for 2 hours (H). Upper panels: repetitive firing traces; values at the start of each trace are RMs.
Lower panels: 3 continuous APs zoomed in from the upper-panel repetitive firing traces; values at the bottom of each trace are AHPA. (I) Cell numbers of
5-HT neurons with (responsive) or without (irresponsive) RM depolarization (> 1 mV) by PPT in various groups. ***P < 0.001. (J) Magnitude of depolarization induced by PPT in various groups. n = 9–18/group. Results are shown as mean ± SEM. **P < 0.01; ***P < 0.001. (K) Changes in firing rate induced by
PPT in various groups. n = 7–18/group. Results are shown as mean ± SEM. ***P < 0.001. (L) Changes in AHPA induced by PPT in various groups. n = 7–18/
group. Results are shown as mean ± SEM. ***P < 0.001.

treatment. At this time, OVXV mice and OVXE mice had comparable body weights. Therefore, the decreased binge-like eating behavior we observed in OVXE mice was not confounded
by body weight divergence or the associated hormonal signals
(e.g., orexin A). In addition, we showed that during the 2.5-hour
period when binge-like eating behavior was assessed, OVXE did
not significantly alter food intake in female mice being exposed
to “continuous” HFD. These observations argue that the effects
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of estrogens on binge-like eating behavior we observed were
independent of the well-known anorexigenic effects of estrogens on basal feeding behavior (35).
Lower circulating estradiol levels have been associated with
increased binge eating in women (7–11). Thus, our finding that
estrogen replacement suppresses binge-like eating behavior in
female mice suggests that estrogen replacement therapy could
be used in ameliorating binge symptoms in women, especially in
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Figure 6. Estrogens inhibit SK-like currents in DRN 5-HT neurons. (A) A voltage clamp protocol to induce SK-like currents. (B) Representative traces for
SK-like currents recorded from a 5-HT neuron before (black) and after (red) apamin perfusion. SK currents were shown as an outward tail current following step depolarization of Vh. (C–E) Representative traces before (black) and after (red) PPT treatment from responsive 5-HT neurons in WT brain slice
(C), from 5-HT neurons in KO brain slice (D), from 5-HT neurons in WT slices preincubated with apamin (100 nM, 2 hours) (E). (F) PPT-induced changes in
SK-like current in WT responsive neurons, in WT irresponsive neurons, in KO 5-HT neurons, or in WT 5-HT neurons preincubated with apamin (100 nM for
2 hours). n = 7–13/group. Results are shown as mean ± SEM. ***P < 0.001. (G) Effects of intra-DRN preinjections of saline or apamin (50 nM, 0.5 μl) on
binge-like eating (2.5-hour HFD intake) in OVXV or OVXE WT and KO female mice. n = 5/group. Results are shown as mean ± SEM. **P < 0.01. (H) Intake
of 0.1 M NaCl solution in OVX WT female mice receiving intra-DRN injections of saline or apamin (50 nM, 0.5 μl) in the CTA tests. n = 4/group. Results are
shown as mean ± SEM.

those after menopause or with menstrual irregularity (4–6). However, due to the broad spectrum of estrogenic actions through multiple estrogen receptors, current estrogen replacement therapy is
often associated with detrimental side effects, such as breast cancer. One solution for this dilemma is to better understand where
and how estrogens act to inhibit binge-like behavior.
Using electrophysiology combined with a genetic mouse
model lacking ERα only in 5-HT neurons, we showed that estrogens, acting via ERα, depolarize DRN 5-HT neurons and stimulate
their firing activities. Notably, impaired brain 5-HT signaling has
been implicated in the development of binge eating. For example,
binge patients are found to have increased 5-HT uptake in the
brain and consequently decreased 5-HT content in the cerebrospinal fluid (14). In addition, effects of 5-HT precursor L-tryptophan
(as measured by prolactin secretion) are significantly blunted in
binge patients, presumably due to dysfunctions of 5-HT receptors and/or 5-HT synthesizing enzyme (TPH2) (14). On the other
hand, drugs that enhance brain 5-HT signals, such as fluoxetine
and d-Fenfluramine, have been shown to suppress binge eating in
patients (17–22, 24, 25). Together, these results raise the possibility
that estrogens may act upon ERα in 5-HT neurons to inhibit bingelike eating. This notion is further supported by our observations
that selective deletion of ERα from 5-HT neurons substantially
blocked effects of OVXE treatment to suppress binge-like eating
behavior in female mice. Collectively, our results pinpointed ERα
expressed by DRN 5-HT neurons as one key site that mediates
estrogenic actions to inhibit binge-like eating behavior.
A recently developed stable GLP-1–estrogen conjugate uses
GLP-1 as a “carrier” to deliver estrogens preferentially to GLP-1
receptor–enriched regions (31). GLP-1–estrogen, like 17β-estradiol,

produces robust estrogen-mediated biological functions (e.g.,
lowering body weight) in mice (31). Importantly, GLP-1–estrogen
does not cause common side effects associated with 17β-estradiol
(e.g., reproductive endocrine toxicity and breast cancer), presumably because this conjugate does not deliver estrogens to the
reproductive organs and breast tissue (31). Notably, body weight–
lowering effects of GLP-1–estrogen conjugate are blunted in ERαKO mice (lacking ERα globally), indicating that the conjugate
acts at least partly via ERα (31). Further, estrogen-mediated body
weight loss is blocked in mice lacking GLP-1 receptors only in the
brain (31), suggesting that this conjugate acts, at least partly, in
the brain regions that express both GLP-1 receptors and estrogen
receptors to produce body weight–lowering effects. Interestingly,
the DRN expresses abundant GLP-1 receptors (32) and ERα (26).
This raises the possibility that GLP-1–estrogen can deliver estrogens to the DRN. Supporting this notion, we demonstrated that
GLP-1–estrogen, at a very low dose (4 μg/kg), stimulated expression of a known estrogen target in the DRN. Remarkably, this
effect of a single dose of GLP-1–estrogen was equivalent to that of
chronic 17β-estradiol pellet supplementation in OVXE mice, suggesting that the GLP-1–estrogen conjugate can efficiently deliver
bioactive estrogens to the DRN. More importantly, we showed
that the single injection of GLP-1–estrogen substantially suppressed binge-like eating behavior in OVX female mice. Notably,
effects of GLP-1–estrogen were more robust than those of GLP-1
alone, indicating that a portion of effects of GLP-1–estrogen on
binge-like eating behavior are mediated by estrogens. Importantly, we showed that these estrogen-mediated inhibitory effects on
binge-like eating behavior were blocked in OVX female mice with
ERα selectively deleted in 5-HT neurons. Together, these results
jci.org   Volume 124   Number 10   October 2014

4357

Research article

indicate that GLP-1–estrogen delivers bioactive estrogens to the
DRN to inhibit binge-like eating behavior partly through acting
upon ERα in DRN 5-HT neurons. Thus, our results provide the
proof-of-concept that ERα expressed by DRN 5-HT neurons is a
suitable target for the treatment of binge eating.
Of course, a portion of effects of GLP-1–estrogen on binge-like
eating behavior stems from GLP-1, as GLP-1 alone also inhibits
binge-like eating behavior in OVX mice. It is well established that
GLP-1 exerts potent anorexigenic effects to suppress basal feeding behavior (36). Recent clinical studies revealed that patients
with binge eating have lower circulating GLP-1 levels compared
with healthy subjects (37, 38). Here, we showed that GLP-1 inhibits binge-like eating behavior, suggesting that GLP-1 could also be
used to treat binge eating in humans. Future studies are therefore
warranted to further delineate the acting sites and the mechanisms underlying the GLP-1 effects on binge eating. Nevertheless, the potent inhibitory effects of GLP-1–estrogen conjugate we
observed in OVX female mice indicate that this conjugate could be
used to ameliorate binge symptoms in women, especially in those
after menopause or with menstrual irregularity.
We further explored the molecular mechanisms by which
estrogen-ERα signals regulate 5-HT neural activities. We made an
interesting observation that all 5-HT neurons depolarized by PPT
(the ERα agonist) exhibit reduced AHPA, phenomena that were
not seen in 5-HT neurons that did not respond to PPT or those
with ERα deleted. Consistent with the notion that AHP is at least
partly constituted by SK currents (33), we further showed that the
PPT failed to suppress AHPA in 5-HT neurons when SK currents
were preinhibited by apamin. In addition, using a voltage clamp
protocol to directly examine SK-like currents, we demonstrated
that PPT inhibited an apamin-sensitive SK-like current in 5-HT
neurons, which was blocked in 5-HT neurons with ERα deletion.
Importantly, inhibition of the SK current (by apamin) blocked
PPT-induced excitation in 5-HT neurons. Collectively, our results
suggest that estrogens act upon ERα to inhibit the SK channels,
which in turn leads to reduced AHPA and consequently increased
excitability of 5-HT neurons.
These electrophysiological results led us to hypothesize that
modulations on the SK current in the DRN may regulate bingelike eating behavior in mice. This is supported by the observation
that intra-DRN injections of apamin suppressed binge-like eating behavior in OVXV WT mice, recapitulating effects of estrogen replacement in OVXE WT mice. Further, we found that the
inhibitory effects of apamin on binge-like eating were not affected
by selective deletion of ERα from 5-HT neurons, arguing that the
SK channel is downstream of ERα signals in 5-HT neurons. These
results clearly indicate that pharmacological inhibition of SK currents in the DRN is sufficient to inhibit binge-like eating behavior
in mice without endogenous estrogens or ERα.
While the current study focused on ERα as one mediator of
estrogens on binge-like eating behavior, our data do not exclude
the possibility that other estrogen receptors, e.g., estrogen
receptor-β (ERβ), may also be involved in the effects of estrogens. Although it has been reported that stimulation of ERβ in
the brain does not regulate basal food intake (39–41), effects
of ERβ signals on binge-like eating behavior cannot be excluded. Indeed, abundance of ERβ is expressed in the DRN (26).
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Thus, future studies are warranted to explore the functions of
ERβ in DRN neurons (or other brain regions) in the context of
binge-like eating.
In summary, our data support a model that estrogens act
upon ERα expressed by DRN 5-HT neurons to inhibit the SK
current, which in turn leads to activation of 5-HT neurons and
ultimately inhibition of binge-like eating behavior in female
mice. Thus, we identified ERα and SK current in DRN 5-HT
neurons as potential targets for anti-binge therapies. Indeed,
we provided evidence that a newly developed GLP-1–estrogen
conjugate can preferentially target this DRN ERα population to
potently inhibit binge-like eating behavior in female mice.

Methods

Mice. We crossed Tph2-CreER (Jackson Laboratory, #016584) transgenic mice and Esr1fl/fl mice (30). This cross produced KO mice (those
that are homozygous for Esr1fl/fl and also carry the Tph2-CreER transgene) and WT mice (those that are homozygous for Esr1fl/fl, but do not
carry the Tph2-CreER transgene). At 8 weeks of age, female KO mice
received i.p. injections of tamoxifen (3 mg/mouse, twice, 24 hours
apart) to induce Cre activity and therefore delete ERα only in 5-HT
neurons. Female WT also received the same tamoxifen injections to
rule out any possible effects of tamoxifen itself. Weekly body weight
of these mice was monitored from weaning till the end of the study.
In parallel, we also crossed the Rosa26-tdTOMATO allele onto
Tph2-CreER mice or Esr1fl/fl Tph2-CreER mice. This cross produced
Tph2-CreER Rosa26-tdTOMATO (WT) and Esr1fl/fl Tph2-CreER Rosa26tdTOMATO (KO) mice. Upon tamoxifen inductions similar to those
described above, both mice expressed TOMATO exclusively in 5-HT
neurons, and KO mice had Esr1 (ERα) deleted specifically in 5-HT neurons. These mice were used for electrophysiology recordings.
All the breeders have been backcrossed to C57BL/6 background
for more than 12 generations. In addition, some C57BL/6 mice
were purchased from the mouse facility of Baylor College of Medicine. Mice were housed in a temperature-controlled environment in
groups of 2 to 5 at 22˚C to 24˚C using a 12-hour light/12-hour dark
cycle. The mice were fed standard chow (6.5% fat, #2920; HarlanTeklad) until training and assessment of binge-like eating behavior.
Water was provided ad libitum.
Histology. We used dual immunofluorescence to examine the
colocalization of ERα and 5-HT in mouse brain. Briefly, C57BL/6
female mice were perfused with 10% formalin, and brain sections
were cut at 25 μm. The sections were incubated at room temperature
in primary goat anti–5-HT antibody (1:5,000, #20079; Immunostar)
overnight, followed by the secondary donkey anti-goat Alexa Fluor
488 (1:500; #A-11055; Invitrogen) for 1.5 hours. Then, the sections
were incubated in the primary rabbit anti-ERα antibody (1:10,000,
#06-935; Millipore) overnight, followed by secondary donkey antirabbit Alexa Fluor 594 (1:500; #A-21207; Invitrogen) for 1.5 hours.
Slides were coverslipped with DAPI-containing mounting media
(H1500; Vector Laboratories). Fluorescence images were analyzed
using a Leica DM5500 fluorescence microscope with OptiGrid
structured illumination configuration.
Similarly, we performed immunofluorescence for 5-HT in
Tph2-CreER Rosa26-tdTOMATO mice to confirm colocalization of
TOMATO and 5-HT. Briefly, mice (after tamoxifen inductions) were
perfused with 10% formalin, and brain sections were cut at 25 μm.
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The sections were incubated at room temperature in primary goat
anti–5-HT antibody (1:5000, #20079; Immunostar) overnight,
followed by the secondary donkey anti-goat Alexa Fluor 488 (1:500,
#A-11055; Invitrogen) for 1.5 hours. Slides were coverslipped with
DAPI-containing mounting media (H1500; Vector Laboratories) and
analyzed using a Leica DM5500 fluorescence microscope with OptiGrid structured illumination configuration. TOMATO signals were
observed directly with a red fluorescence channel. As a negative control, TOMATO signals were also examined in Tph2-CreER Rosa26tdTOMATO mice without tamoxifen induction.
We also performed immunohistochemistry for ERα in WT and
KO mice to validate selective deletion of ERα in 5-HT neurons. Briefly,
mice (after tamoxifen inductions) were perfused with 10% formalin,
and brain sections were cut at 25 μm. The sections were incubated at
room temperature in the primary rabbit anti-ERα antibody (1:20,000;
Upstate) overnight followed by biotinylated anti-rabbit secondary
antibody (1:1,000; Vector) for 2 hours. Sections were then incubated
in the avidin-biotin complex (1:500, ABC; Vector Elite Kit) and incubated in 0.04% 3, 3′-diaminobenzidine and 0.01% hydrogen peroxide. After dehydration through graded ethanol, the slides were then
immersed in xylene and coverslipped. Images were analyzed using a
brightfield Leica microscope.
Training and assessment of binge-like eating behavior. We used the
published protocol (29) to train and assess binge-like eating behavior
in mice. Briefly, mice were randomly assigned into “intermittent” or
“continuous” group. “Intermittent” mice were exposed to both regular chow pellets (6.5% fat, #2920; Harlan) and HFD pellets (40% fat,
TD.95217; Harlan) for 48 hours (from Monday 11:00 am to Wednesday
11:00 am) and then exposed to only chow for the rest of the week. On
the binge assessment day (Monday of the 2nd week), HFD was given
back to cages at 11:00 am, and HFD and chow intake were measured
for 2.5 hours (from 11:00 am to 1:30 pm). The “continuous” group was
exposed to chow and HFD for the entire study, and HFD and chow
intake were measured for 2.5 hours at the same time as in the “intermittent” group. Mice were housed in their original home cages for the
entire training and study period. These cages (width: 7.25 inch, length:
11.5 inch, height: 5 inch; # RC71U-UD; Alternative Design) were made
of polysulfone, with a gridded metal top holding a water bottle and pellet diets. A metal board was vertically inserted into the food holder to
separate chow and HFD pellets.
Binge-like eating behavior in OVXV and OVXE mice. Female littermates were anesthetized with isoflurane. As previously described (42,
43), bilateral OVX was performed, followed by s.c. implantations of a
pellet containing 17β-estradiol (0.5 μg/d for 60 days, OVXE) or containing vehicle (OVXV). These pellets were purchased from Innovative Research of America. After a 7-day recovery, mice were subjected
to the intermittent or continuous (as control) exposure to HFD for 1
week in order to induce binge-like eating behavior. Two weeks after
the surgery, binge-like eating behavior was assessed as detailed above.
Body weight and food intake were monitored every other day during the entire study period. Body composition was determined using
quantitative magnetic resonance on the same day when binge-like
behavior was assessed. After assessment of binge-like eating behavior, mice were deeply anesthetized with isoflurane, and blood was collected through cardiac aspiration. Plasma was obtained by centrifugation, and plasma orexin A was measured with a mouse orexin A ELISA
kit (MBS815052; MyBioSource).
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Effects of GLP-1–estrogen on binge-like eating behavior in OVX female
mice. First, to determine whether stable GLP-1–estrogen delivers
bioactive estrogens into mouse DRN, we examined effects of GLP1–estrogen on expression of Trim25 (a known estrogen target) in the
DRN. To this end, female C57BL/6 mice (12 weeks of age) received
OVX surgery as described above. After a 7-day recovery, these mice
received s.c. injections of GLP-1 (4 μg/kg) or GLP-1–estrogen (4 μg/kg).
Two hours after injections, mice were sacrificed and the DRN was
quickly microdissected and stored at –80˚C. As control groups, another cohort of female C57BL/6 mice (12 weeks of age) received OVXV
or OVXE surgery as described above. After a 7-day recovery, the DRN
was quickly microdissected and stored at –80˚C. As described previously (44), total mRNA was isolated using TRIzol Reagent (Invitrogen)
according to the manufacturer’s protocol, and reverse transcription
reactions were performed from 2 μg of total mRNA using a HighCapacity cDNA Reverse Transcription Kits (Invitrogen). Samples were
amplified on a CFX384 Real-Time System (Bio-Rad) using SsoADV
SYBR Green Supermix (Bio-Rad). Correct melting temperatures for
all products were verified after amplification. Results were normalized against the expression of housekeeping gene cyclophilin. Primer
sequences were as follows: cyclophilin, forward: TGGAGAGCACCAAGACAGACA; cyclophilin, reverse: TGCCGGAGTCGACAATGAT; Trim25, forward: TGATGTGGCTGTGCATGATA; Trim25,
reverse: AAGACCTGCTCCCCTACGAC.
Further, we tested to determine whether GLP-1–estrogen can
inhibit binge-like eating behavior via acting upon ERα in 5-HT neurons. To this end, WT and KO female mice received tamoxifen inductions as described above at 8 weeks of age. At 24 weeks of age, these
WT and KO mice were anesthetized with isoflurane and received bilateral OVX surgery. After a 7-day recovery period, mice were subjected
to the 1-week intermittent HFD exposure to induce binge-like eating
behavior as described above. On the binge assessment day, vehicle
(saline), GLP-1 (4 μg/kg), or GLP-1–estrogen (4 μg/kg) was s.c. injected at 10:30 am, followed by assessment of binge-like eating behavior
(11:00 am to 1:30 pm). The doses of GLP-1 and GLP-1–estrogen were
chosen based on the previous report (31) and our preliminary studies.
Effects of intra-DRN injections on binge-like eating behavior in OVX
female mice. WT and KO female mice received tamoxifen induction
as described above at 8 weeks of age. At 24 weeks of age, mice were
anesthetized with i.p. injections of the ketamine/xylazine cocktail
(100 mg/kg ketamine and 10 mg/kg xylazine) and received OVXV or
OVXE treatment as described above. During the same period under
anesthesia, an indwelling microinjection cannula was stereotaxically
inserted to target the DRN (midline, 4.36 mm posterior and 3.1 ventral to the bregma). After a 7-day recovery, mice were subjected to the
1-week intermittent HFD exposure to induce binge-like eating behavior as described above. On the binge assessment day, vehicle (saline)
or apamin (50 nM, 0.5 μl, # STA-200; Alomone Labs) was injected
into the DRN at 10:30 am, followed by assessment of binge-like eating
behavior (11:00 am to 1:30 pm). The dose of apamin was chosen based
on preliminary studies.
Conditioned taste-aversion tests. To rule out the possibility that
intra-DRN injections of apamin inhibit binge-like eating behavior through nonspecific adverse effects, we performed conditioned
taste aversion (CTA) tests as described in the literature (45). Briefly,
C57BL/6 female mice (12 weeks of age) were bilaterally ovariectomized, and during the same period under anesthesia, an indwelling
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cannula was inserted to target the DRN as described above. After a
7-day recovery, these mice were housed individually and acclimated
to intra-DRN injections (saline solutions) and a 2-hour daily water
supply (3:00 pm–5:00 pm) over 8 days. On a test day, mice were given access to 0.2 m NaCl solution for 2 hours (3:00 pm–5:00 pm) in
the same type of bottle with which they were usually presented with
water. Immediately after exposure to the NaCl solution, mice received
intra-DRN injections of saline or apamin (50 nM, 0.5 μl). The amount
of solution intake was measured. The same tests were repeated in
another 5 trials every other day.
Anxiety tests (light-dark test and EPM). To determine whether
intermittent HFD exposure causes anxiety in mice, an independent
cohort of C57BL/6 female mice (12 weeks) were subjected to intermittent or continuous HFD exposure for 1 week as described above.
Binge-like eating behavior was confirmed in the “intermittent”
HDF group in the second week. At 11:00 am on Monday of the third
week (the same time when mice would be tested for binge-like eating behavior), these mice were subjected to the light-dark tests using
published protocol (46). Briefly, the test consisted of a polypropylene
chamber (44 × 21 × 21 cm) unequally divided into a larger, brightly
illuminated open compartment (clear polypropylene) and a smaller,
dark compartment (in dark polypropylene), connected by a small
opening. Mice were placed in the illuminated chamber and allowed
to move freely between the 2 chambers for 10 minutes. The latency
to enter the light and dark chambers, the time spent in the chambers,
the total number of transitions, and distance traveled in each chamber was measured using the VersaMax Animal Activity Monitoring
System (AccuScan Instruments Inc.) and analyzed. Transfer of all 4
paws of an experimental animal from one chamber to the other was
considered as 1 transition event.
At 11:00 am on Tuesday of the third week, these mice were subjected to the EPM using published protocol (46). The EPM was constructed of Plexiglas, with 2 open arms (30 × 5 cm) and 2 enclosed
black arms (30 × 5 × 15 cm) at an elevation of 50 cm above the floor.
The arms of the maze form a cross, with the 2 open arms facing each
other. The maze was cleaned with 70% ethanol solution after each
session and allowed to dry between the sessions. Anxiety-like behavior was measured by placing the mice in the center of the junction
of the arms of the maze facing an open arm, and the behavior was
analyzed for 10 minutes. The number of entries into the open and
closed arms, the time spent exploring the open and closed arms, and
the distance traveled were recorded and analyzed using the ANYmaze software (Stoelting Co.). The changes in anxiety-like behavior
were calculated by dividing the number of entries into the open arms
by the total number of entries into all 4 arms (open to total ratio for
entries) or by dividing the amount of time spent in the open arms by
the amount of time spent in all 4 arms (OTR for time). The time spent
in the center platform not exploring any of the arms was not included
in these calculations.
Forced swim tests. To determine whether the intermittent HFD
exposure causes depression in mice, an independent cohort of
C57BL/6 mice was subjected to the intermittent or continuous HFD
exposure for 1 week as described above. Binge-like eating behavior
was confirmed in the intermittent HDF group in the second week.
At 11:00 am on Monday of the third week (the same time when mice
would be tested for binge-like eating behavior), these mice were
subjected to the forced swim tests using published protocol (47–49).
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Briefly, the mice were individually placed into a glass cylinder (25
cm tall × 10 cm diameter) containing 8 cm of water, maintained
at 23°C to 25°C for 6 minutes. The mouse movement was digitally
recorded from the side using a camcorder. Water in the cylinder
was replaced after each recording. The starting and total time of
immobility for each mouse was recorded. Immobility is defined as
the absence of active floating with only minimal movements needed
to keep head above water. The immobility was scored every 30 seconds for the last 4 minutes. During each 30 seconds, 1 immobility
score was recorded if the immobility time was more than 10 seconds. Data from mice that had difficulty keeping heads above water
were excluded from analyses. All the videos were blindly rated by a
different experimenter.
Electrophysiology. Mice were deeply anesthetized with isoflurane
and transcardially perfused (50) with a modified ice-cold artificial
cerebral spinal fluid (aCSF) in: 10 mM NaCl, 25 mM NaHCO3, 195 mM
sucrose, 5 mM glucose, 2.5 mM KCl, 1.25 mM NaH2PO4, 2 mM sodium
pyruvate, 0.5 mM CaCl2, and 7 mM MgCl2) (51). The mice were then
decapitated, and the entire brain was removed. Brains was quickly
sectioned in ice-cold aCSF solution (126 mM NaCl, 2.5 mM KCl,
1.2 mM MgCl2, 2.4 mM CaCl2, 1 mM NaH2PO4, 11.1 mM glucose, and
mM 21.4 NaHCO3) (52) saturated with 95% O2 and 5% CO2. Coronal
sections containing the DRN (270 μm) were cut with a Microm HM
650V vibratome (Thermo Scientific) and then preincubated in the
aCSF (52) at 34°C for at least 1 hour before recording.
Whole-cell patch clamp recordings were performed in the target neurons in the DRN visually identified by an upright microscope (Eclipse FN-1; Nikon) equipped with IR-DIC optics (×40 NIR;
Nikon). Signals were processed using Multiclamp 700B amplifier
(Axon Instruments), sampled using Digidata 1440A, and analyzed
offline on a PC with pCLAMP 10.3 (Axon Instruments). The slices
were bathed in oxygenated aCSF (52) (32°C–34°C) at a flow rate of
approximately 2 ml/min. Patch pipettes with resistances of 3 to 5
MΩ were filled with solution containing 126 mM K gluconate, 10
mM NaCl, 10 mM EGTA, 1 mM MgCl2, 2 mM Na-ATP, and 0.1 mM
Mg-GTP (adjusted to pH 7.3 with KOH) (34). Voltage clamp was
used to record SK-like currents. Current clamp was engaged to test
neural firing, RM, and input resistance. Based on previous reports
and our preliminary data, PPT (100 nM, perfusion up to 6 minutes
at 2 ml/min; Sigma-Aldrich, H6036) (53), acute apamin perfusion
(100 nM, perfusion upon to 8 minutes at 2 ml/min), and chronic
apamin incubation (100 nM, incubation about 2 hours) (34) were
used. Alexa Fluor 488 (0.01 mM) was included in the pipette solution to trace the recorded neurons. After recordings, slices were
fixed with 4% formalin overnight and mounted onto slides. Cells
were then visualized with the a Leica DM5500 fluorescence microscope to identify post hoc the anatomical location of the recorded
neurons in the DRN.
Statistics. The data are presented as mean ± SEM. Statistical
analyses were performed using GraphPad Prism. Most data were analyzed by 1- or 2-way ANOVA, followed by post hoc Bonferroni’s tests.
Comparisons between 2 groups were analyzed by t tests. Numbers of
responsive neurons in each group were analyzed by χ2 tests. P < 0.05
was considered statistically significant.
Study approval. Care of all animals and procedures were
approved by the Baylor College of Medicine Institutional Animal
Care and Use Committee.
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